HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Preloaded Syringe for Wet AMD Approved

The FDA has approved Genentech's prefilled ranibizumab syringe for injecting the eyes of people with wet age-related macular degeneration (wet AMD)

The US Food and Drug Administration (FDA) has approved a pre-filled syringe to administer ranibizumab (Lucentis PFS/Genentech-Roche).

The device will be available early next year.

Like the Lucentis 0.5mg vial, the syringe is approved to treat people with wet age-related macular degeneration (AMD) and macular edema after retinal vein occlusion (RVO).

Having a prefilled syringe should make it easier and safer for physicians to administer the eye injection, the company said in a news release.

An estimated 1.1 million people in the US have wet AMD. The drug was approved to treat the condition in 2006.

It is a vascular endothelial growth factor inhibitor designed to bind to and inhibit the protein that plays a role in angiogenesis and hyperpermeability of blood vessels.